Owlstone and Agilent Technologies Collaborate to Explore FAIMS/TOF-MS Applications
News Jun 09, 2009
Owlstone Nanotech Inc., a subsidiary of Advance Nanotech Inc., and Agilent Technologies Inc. announced a phase one agreement to develop Owlstone’s field-asymmetric ion mobility spectrometry (FAIMS) filter as a front-end separation module for Agilent’s Accurate Mass time-of-flight mass spectrometers (TOF-MS).
The goal is to determine how the systems can work together to enable identification of previously unresolved analytes. The collaboration will also explore how FAIMS can speed up liquid chromatographic separations, saving valuable analysis time.
Financial details were not disclosed.
“The collaboration with Agilent gives us the opportunity to integrate our technology onto highly sensitive mass spectrometers that are ideal for demonstrating the benefit of the uniquely high-field, fast scanning ability of our FAIMS device,” said Bret Bader, Owlstone CEO.
Bader continued, “Partnerships with highly-skilled organizations like Agilent are a key part of our business strategy. We view this alliance with a recognized industry leader as a further stride in the realization of this strategy and a testament to the quality we strive to achieve at Owlstone; and we are very excited by the potential of these collaborative efforts to bring new analytical capabilities to a world-wide market.”
“The fast scanning speed of the Owlstone micro-scale FAIMS device now makes it feasible to acquire ion mobility spectra from LC/MS separations in real time,” said John Fjeldsted, Agilent LC/MS Research and Development director. “In particular, our TOF and QTOF systems with Agilent Jet Stream Technology are uniquely suited for coupling to high-speed ion mobility separations by virtue of very high spectral acquisition rates and an excellent analyte desolvation design.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Penn Medicine Biochemist Receives Major Award for Research on Epigenetic Protein Modifications via Mass SpecNews
Benjamin A.Garcia, PhD, an expert in quantitative proteomics and Presidential Professor of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania, has been awarded the Biemann Medal by the American Society for Mass Spectrometry (ASMS). The early-career award recognizes significant achievement in basic or applied mass spectrometry.